Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization

Critical Care Medicine

Volumn 35, Issue 5, 2007, Pages 1296-1301

  Chen, John C ^a   Kaul, Padma ^b   Levy, Jerrold H ^c   Haverich, Axel ^d   Menasché, Philippe ^e   Smith, Peter K ^f   Carrier, Michel ^g   Verrier, Edward D ^h   Van De Werf, Frans ⁱ   Burge, Russel ^j   Finnegan, Paul ^k   Mark, Daniel B ^f   Shernan, Stanton K ^l  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Leibniz Forschungslaboratorien für Biotechnologie und künstliche Organe   (Germany)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g MONTREAL HEART INSTITUTE   (Canada)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^k ALEXION PHARMACEUTICALS   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Coronary artery bypass graft; Costs and cost analysis; Hospital costs; Myocardial infarction; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEART INFARCTION; HOSPITAL BILLING; HOSPITALIZATION COST; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

EID: 34247376980     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000262403.08546.A2     Document Type: Article

References (25)

1. DeFrances CJ, Podgornik MN: 2004 National Hospital Discharge Survey. Advance data from vital and health statistics; no. 371. Hyattsville, MD, National Center for Health Statistics, 2006
2. Mathew JP, Parks R, Savino JS, et al: Atrial fibrillation following coronary artery bypass graft surgery: Predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. JAMA 1996; 276:300-306
3. Newman MF, Kirchner JL, Phillips-Bute B, et al: Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 2001; 344:395-402
4. SoS Investigators: Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): A randomised controlled trial. Lancet 2002; 360:965-970
5. Stover EP, Siegel LC, Parks R, et al: Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: A 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology 1998; 88:327-333
6. Healthcare Cost and Utilization Project (HCUP): Weighted national estimates from HCUP Nationwide Inpatient Sample. Available at: http://www.ahrq/HCUPnet/. Accessed October 24, 2005
7. Puskas JD, Williams WH, Mahoney EM, et al: Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: A randomized trial. JAMA 2004; 291:1841-1849
8. Weintraub WS, Becker ER, Mauldin PD, et al: Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST). Am J Cardiol 2000; 86:747-752
9. Nagle PC, Smith AW: Review of recent US cost estimates of revascularization. Am J Manag Care 2004; 10:S370-S376
10. Verrier ED, Shernan SK, Taylor KM, et al: Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. JAMA 2004; 291:2319-2327
11. Charles E, Mark DB: The economics of percutaneous intervention. In: Interventional Cardiovascular Medicine: Principles and Practice. Roubin GS, Califf R, O'Neill WW, et al. (Eds). New York, Churchill Livingstone, 2004, pp 373-384
12. Mark DB: Medical economics in interventional cardiology. In: Textbook of Interventional Cardiology. Topol EJ (Ed). Philadelphia, Harcourt Health Sciences, 2002, pp 999-1020
13. Hlatky MA, Lipscomb J, Nelson C, et al: Resource use and cost of initial coronary revascularization. Coronary angioplasty versus coronary bypass surgery. Circulation 1990; 82:IV208-IV213
14. Hsiao WC, Braun P, Dunn D, et al: Results and policy implications of the resource-based relative-value study. N Engl J Med 1988; 319:881-888
15. Ferguson TB Jr, Hammill BG, Peterson ED, et al: A decade of change-Risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: A report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg 2002; 73:480-489
16. Haverich A, Shernan S, Levy J, et al: Pexelizumab reduces death and myocardial infarction in high risk cardiac surgical patients. Ann Thorac Surg 2006; 82:486-492
17. Al Suwaidi J, Berger PB, Holmes DR Jr: Coronary artery stents. JAMA 2000; 284:1828-1836
18. Fellahi JL, Gue X, Richomme X, et al: Short-and long-term prognostic value of postoperative cardiac troponin I concentration in patients undergoing coronary artery bypass grafting. Anesthesiology 2003; 99:270-274
19. Klatte K, Chaitman BR, Theroux P, et al: Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: Results from the GUARDIAN trial. J Am Coll Cardiol 2001; 38:1070-1077
20. Onorati F, De FM, Mastroroberto P, et al: Determinants and prognosis of myocardial damage after coronary artery bypass grafting. Ann Thorac Surg 2005; 79:837-845
21. Ramsay J, Shernan S, Fitch J, et al: Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves. J Thorac Cardiovasc Surg 2005; 129:300-306
22. Shernan SK, Fitch JC, Nussmeier NA, et al: Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004; 77:942-949
23. Steuer J, Horte LG, Lindahl B, et al: Impact of perioperative myocardial injury on early and long-term outcome after coronary artery bypass grafting. Eur Heart J 2002; 23:1219-1227
24. Aranki SF, Shaw DP, Adams DH, et al: Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996; 94:390-397
25. Eagle KA, Guyton RA, Davidoff R, et al: ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340-e437